Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Multicenter Randomized Double-Blind Double-Dummy Parallel Group Study of 3-Month or 6-Month Treatment With SSR126517E [Idrabiotaparinux-sodium] (3.0 mg s.c. Once-Weekly) Versus Oral INR-Adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis

X
Trial Profile

An International Multicenter Randomized Double-Blind Double-Dummy Parallel Group Study of 3-Month or 6-Month Treatment With SSR126517E [Idrabiotaparinux-sodium] (3.0 mg s.c. Once-Weekly) Versus Oral INR-Adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idrabiotaparinux sodium (Primary) ; Avidin; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms CASSIOPEA
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Nov 2011 Primary endpoint 'Venous-thromboembolism-event-rate' has been met acording to results published in the Lancet
    • 28 Nov 2011 Results published in the Lancet.
    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top